Navigation Links
Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020
Date:7/4/2012

NEW YORK, July 4, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020

http://www.reportlinker.com/p0843058/Ovarian-Cancer-Therapeutics---Global-Drug-Forecasts-and-Treatment-Analysis-2020.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020

Summary

GlobalData, the industry analysis specialist, has released its new report, "Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020". The report is an essential source of information and analysis on the global ovarian cancer therapeutics market. The report provides comprehensive information on ovarian cancer, highlighting the treatment guidelines. It identifies and analyses the key trends shaping and driving the global ovarian cancer therapeutics market. It analyses the treatment usage patterns in the global ovarian cancer therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global ovarian cancer sector. It quantifies the unmet need in the global ovarian cancer therapeutics market as well as in the individual markets such as the US and the top five countries in Europe, highlighting the opportunity for future players.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

The ovarian cancer therapeutics market grew at a Compound Annual Growth Rate (CAGR) of only 1.0% between 2002 and 2011. The patent expiries of major branded products, such as Taxol (paclitaxel), Paraplatin (carboplatin), Gemzar (gemcitabine), Hycamtin (topotecan hydrochloride) and the subsequent launch of generics, have acted as restraining factors to the market. The introduction of new and promising therapies such as Avastin (bevacizumab), AMG 386, EC145, Farletuzumab (MORAb-003), Karenitecin (BNP1350), OPAXIO (paclitaxel poliglumex), OPT-821, Paclical (paclitaxel), Vargatef (BIBF 1120) and Votrient (pazopanib) are expected to drive the market from 2011–2020.

In 2011, the ovarian cancer therapeutics markets in key countries (the US, the UK, Germany, France, Italy, Spain, Japan, Brazil, Russia, India and China) were worth $736.7m collectively. The ovarian cancer therapeutics market is expected to witness three-fold growth by 2020, reaching $2,352m at a CAGR of 13.8%. This high growth rate is expected due to the strength of the pipeline candidates, which are anticipated to change the treatment paradigm of ovarian cancer when launched.

Scope

The scope of the report includes -

- An overview of ovarian cancer which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.

- Annualized global ovarian cancer therapeutics market revenue, annual cost of therapy and treatment usage patterns data by stage of the disease from 2002 to 2010, forecast for 10 years to 2020.

- Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France Japan and BRIC countries that include Brazil, Russia, India and China

- Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events.

- Competitor assessment including drug launch analysis and drug sales forecasts.

- Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, LCM activities, product positioning and drug sales forecast.

- Analysis of unmet need in the market and target product profile including opportunity for target product.

- Technology trends analytic framework to assess strength of pipeline.

- Pipeline analysis data providing a split by stage of the disease and line of therapy across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include microtubule stabilizers, vascular endothelial growth factor receptor (VEGFR) inhibitors, immunomodulators, folate receptor inhibitors, poly ADP ribose polymerase (PARP) inhibitors, topoisomerase inhibitors, interleukins, mammalian target of rapamycin (mTOR) inhibitors and phosphatidylinositol-3-kinase (PI3K) inhibitors.

- Clinical trials mapping of trials for ovarian cancer in different regions.

- An overview of the most promising drugs' including clinical study details, efficacy, safety, collaboration agreements, marketing rights, and launch analysis and drug sales forcasts to 2020.

- Analysis of the current and future market competition in the global ovarian cancer therapeutics market.

- Company profiles including business description, financial overview and SWOT analysis. Key future market players covered include F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Amgen Inc, AstraZeneca PLC, Boehringer Ingelheim GmbH, Oasmia Pharmaceutical AB, Endocyte, Inc, BioNumerik Pharmaceuticals, Inc, Eisai Inc., Cell Therapeutics, Inc, and Menarini Group,

- Analysis of licensing agreements during 2008-2010 in the ovarian cancer therapeutics market. M&A analysis which includes M&A deals by size and geography.

- Strategic assessment of the market through market impact analysis, future market scenario and company analysis.

- Direct quotes from key opinion leaders (KOL) or physicians in the ovarian cancer therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop business strategies and perform superior market quantification analysis by

- Understanding the trends shaping and driving the global ovarian cancer therapeutics market.

- Understanding treatment preferences of physicians in disease state and across treatment flow.

- Accessing market sizing, forecasts and quantified growth opportunities in the global ovarian cancer therapeutics market till 2020.

- Quantifying patient population in the global ovarian cancer market to better design product pricing & launch plans.

- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by

- performing benchmarking analysis and growth opportunities against currently marketed products

- Identifying market entry points based on safety, efficacy, and pricing parameters.

- Assessing competitiveness of products in market by understanding the strength and weakness of current competition.

- Develop and design your in-licensing and out-licensing strategies by

- Taking a comprehensive look of at the disease pipeline and identifying most promising paradigm shifting products.

- Assessing strength of pipeline bases on first in class, me-too, generic and lifecycle management of products.

- Track drug sales in the global ovarian cancer therapeutics market from 2002 to 2020

- Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.

- What's the next big thing in the global ovarian cancer therapeutics market landscape? Identify, understand and capitalize.

Keywords

Market forecast, revenues, unmet need, drivers, barriers, pharma, clinical trials, marketed products, pipeline, promising drugs, future players, key companies, strategic competitor assessment, market characterization, implications for future market, mechanism of action, oncology, cancer, treatment guideline, target product profile, clinician's endpoints, disease overview, colorectal cancer drug sales, US colorectal cancer market, UK colorectal cancer market, France colorectal cancer market, Germany colorectal cancer market, Italy colorectal cancer market, Spain colorectal cancer market, Japan colorectal cancer market, BRIC colorectal cancer market, Brazil, Russia, India, China

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 8

1.2 List of Figures 11

2 Ovarian Cancer Therapeutics - Disease Overview 16

2.1 Overview 16

2.1.1 Types of Ovarian Cancer 16

2.2 Staging and Treatment of Ovarian Cancer 17

2.2.1 Stage I 21

2.2.2 Stage IA 21

2.2.3 Stage IB 21

2.2.4 Stage IC 21

2.2.5 Stage II 21

2.2.6 Stage IIA 21

2.2.7 Stage IIB 21

2.2.8 Stage IIC 21

2.2.9 Stage III 22

2.2.10 Stage IIIA 22

2.2.11 Stage IIIB 22

2.2.12 Stage IV 22

2.3 Epidemiology 22

2.4 Etiology 22

2.5 Symptoms 23

2.6 Risk Factors 23

2.7 Diagnosis 24

2.7.1 Physical Examination 24

2.7.2 Blood Tests 24

2.7.3 Human Chorionic Gonadotropin (hCG) Test 26

2.7.4 Ultrasound and CT Scans 26

2.7.5 Biopsy 26

2.8 Pathology 27

2.8.1 Grading 27

2.9 Prognosis 27

2.10 Treatment 28

2.10.1 Surgery 28

2.10.2 Chemotherapy 29

2.10.3 Radiation Therapy 29

2.11 Treatment Options by Stage 29

2.11.1 Stage IA 29

2.11.2 Stage IB 29

2.11.3 Stage IC 30

2.11.4 Stage IIA 30

2.11.5 Stage IIB, Stage IIC, Stage IIIA, Stage, IIIB, Stage IIIC, Stage IV 30

2.11.6 Treatment Follow-Up 30

2.12 Chemotherapy Regimens 32

2.13 GlobalData In-Depth Report Guidance 33

3 Ovarian Cancer Therapeutics - Market Characterization 34

3.1 Global 34

3.1.1 Market Size 34

3.1.2 Drivers and Restraints 42

3.1.3 Forecasts 45

3.1.4 Drug Sales 54

3.2 The US 56

3.2.1 Market Size 56

3.2.2 Drivers and Restraints 63

3.2.3 Forecasts 66

3.2.4 Drug Sales 73

3.2.5 Pricing and Reimbursements 75

3.3 The UK 76

3.3.1 Market Size 76

3.3.2 Drivers and Restraints 84

3.3.3 Forecasts 87

3.3.4 Drug Sales 96

3.3.5 Pricing and Reimbursements 98

3.4 Germany 99

3.4.1 Market Size 99

3.4.2 Drivers and Restraints 107

3.4.3 Forecasts 110

3.4.4 Drug Sales 119

3.4.5 Pricing and Reimbursements 121

3.5 France 122

3.5.1 Market Size 122

3.5.2 Drivers and Restraints 130

3.5.3 Forecasts 132

3.5.4 Drug Sales 141

3.5.5 Pricing and Reimbursements 143

3.6 Italy 144

3.6.1 Market Size 144

3.6.2 Drivers and Restraints 152

3.6.3 Forecasts 155

3.6.4 Drug Sales 164

3.6.5 Pricing and Reimbursements 166

3.7 Spain 167

3.7.1 Market Size 167

3.7.2 Drivers and Restraints 175

3.7.3 Forecasts 178

3.7.4 Drug Sales 187

3.7.5 Pricing and Reimbursements 189

3.8 Japan 190

3.8.1 Market Size 190

3.8.2 Drivers and Restraints 198

3.8.3 Forecasts 201

3.8.4 Drug Sales 210

3.8.5 Pricing and Reimbursements 212

3.9 Brazil 213

3.9.1 Market Size 213

3.9.2 Patient Volume 216

3.9.3 Drivers and Restraints 220

3.9.4 Impact on the Market 222

3.9.5 Forecasts 223

3.9.6 Future Impact 229

3.10 Russia 230

3.10.1 Market Size 230

3.10.2 Drivers and Restraints 236

3.10.3 Impact on the Market 238

3.10.4 Forecasts 239

3.10.5 Future Impact 245

3.11 India 246

3.11.1 Market Size 246

3.11.2 Drivers and Restraints 253

3.11.3 Impact on the Market 255

3.11.4 Forecasts 256

3.11.5 Future Impact 263

3.12 China 264

3.12.1 Market Size 264

3.12.2 Drivers and Restraints 271

3.12.3 Impact on the Market 273

3.12.4 Forecasts 274

3.12.5 Future Impact 280

3.13 Key Takeaway 280

4 Ovarian Cancer Therapeutics - Opportunity and Unmet Need 281

4.1 Unmet Need 281

4.2 First-Line Treatment of Loco-Regional and Advanced/Metastatic Setting 282

4.3 Second-Line Treatment of Loco-Regional and Advanced/Metastatic Setting 283

4.4 Key Takeaway 283

5 Ovarian Cancer Therapeutics - Competitive Assessment 284

5.1 Strategic Competitor Assessment 284

5.1.1 Benchmarking 284

5.1.2 Current Competitor Assessment 292

5.1.3 Chemotherapy 293

6 Ovarian Cancer Therapeutics - Strategic Assessment 294

6.1 Key Events Impacting the Future Market 294

6.2 Market Impact Analysis 295

6.3 Future Market Scenario 296

7 Product Profiles for the Major Marketed Products in the Ovarian Cancer Market 297

7.1.1 Carboplatin 297

7.1.2 Cisplatin 304

7.1.3 Paclitaxel 308

7.1.4 Altretamine 314

7.1.5 Hycamtin (topotecan hydrochloride) 317

7.1.6 Gemzar (gemcitabine) 322

7.1.7 Yondelis (trabectedin) 326

7.1.8 Doxil (doxorubicin Hcl liposome injection) 331

7.2 Partners in Commercialization 336

7.2.1 Taj Pharmaceuticals Enters Into License Agreement with AstraZeneca Pharmaceuticals for Gemcitabine HCI 336

7.2.2 APP Pharmaceuticals Enters Into Licensing Agreement with Teva Pharmaceutical for Gemcitabine HCI 336

7.3 Key Takeaway 336

8 Ovarian Cancer - Pipeline Assessment 337

8.1 Overview 337

8.2 Pipeline Analysis by Phase of Development 337

8.3 Pipeline by Mechanism of Action 338

8.4 Pipeline by Line of Therapy 339

8.5 Strategic Pipeline Assessment 340

8.5.1 Technology Trends Analytic Framework 340

8.6 Ovarian Cancer Pipeline – Pipeline by Clinical Phases of Development 342

8.6.1 Ovarian Cancer – Pre-Registration Clinical Pipeline 342

8.6.2 Ovarian Cancer – Phase III of the Clinical Pipeline 343

8.6.3 Ovarian Cancer – Phase II of the Clinical Pipeline 344

8.6.4 Ovarian Cancer – Phase I of the Clinical Pipeline 348

8.6.5 Ovarian Cancer – Preclinical Pipeline 350

8.6.6 Ovarian Cancer – Discovery Stage Pipeline 351

8.7 Most Promising Drug Profiles 351

8.7.1 Avastin (bevacizumab) 351

8.7.2 Paclical (paclitaxel) 354

8.7.3 Votrient (pazopanib) 355

8.7.4 Farletuzumab (MORAb-003) 357

8.7.5 Karenitecin (BNP 1350) 359

8.7.6 Opaxio (xyotax, CT-2103) 361

8.7.7 AMG 386 364

8.7.8 EC-145 365

8.7.9 Recentin (cediranib, AZD2171) 367

8.7.10 Vargatef (BIBF 1120) 368

8.8 Partners in Research and Development 370

8.8.1 Licensing Agreements 370

8.8.2 Co-development Agreements 372

8.9 Key Takeaway 375

9 Ovarian Cancer Therapeutics - Clinical Trials Mapping 376

9.1 Clinical Trials 376

9.1.1 Clinical Trials by Status 376

9.1.2 Clinical Trials by Country 377

9.1.3 Clinical Trials by Phase 378

9.1.4 Clinical Trials by Sponsor Type 379

9.1.5 Clinical Trials – Leading Sponsors 380

9.1.6 Clinical Trials – Leading Company Sponsors by Phase 381

9.2 Patient Recruitment 382

10 Ovarian Cancer Therapeutics - Future Market Players 383

10.1 F. Hoffmann-La Roche Ltd. 383

10.1.1 Business Description 383

10.1.2 Financial Overview 383

10.1.3 SWOT Analysis 384

10.2 Menarini Group 389

10.2.1 Business Description 389

10.2.2 Financial Overview 389

10.2.3 SWOT Analysis 390

10.3 GlaxoSmithKline plc. 394

10.3.1 Business Description 394

10.3.2 Financial Overview 394

10.3.3 SWOT Analysis 395

10.4 Eisai Inc., 400

10.4.1 Business Description 400

10.4.2 Financial Overview 401

10.4.3 SWOT Analysis 401

10.5 Cell Therapeutics, Inc. 404

10.5.1 Business Description 404

10.5.2 Financial Overview 404

10.5.3 SWOT Analysis 405

10.6 Amgen Inc. 408

10.6.1 Business Description 408

10.6.2 Financial Overview 409

10.6.3 SWOT Analysis 410

10.7 AstraZeneca PLC 414

10.7.1 Business Description 414

10.7.2 Financial Overview 415

10.7.3 SWOT Analysis 415

10.8 Boehringer Ingelheim GmbH 419

10.8.1 Business Description 419

10.8.2 Financial Overview 419

10.8.3 SWOT Analysis 420

10.9 Oasmia Pharmaceutical AB 424

10.9.1 Business Description 424

10.9.2 Financial Overview 424

10.10 Endocyte, Inc. 424

10.10.1 Business Description 424

10.11 BioNumerik Pharmaceuticals, Inc. 424

10.11.1 Business Description 424

11 Ovarian Cancer Therapeutics - M&A Analysis 425

11.1 Key Highlights 425

11.1.1 M&A Agreements by Phase of Development 425

12 Ovarian Cancer Therapeutics - Expert Opinion 427

12.1 Important Data and Analysis from Key Opinion Leaders (KOLs) 427

12.1.1 Treatment Options (Surgery/Chemotherapy) 427

12.1.2 Treatment Options by Stage 427

12.1.3 Number of Chemotherapy Cycles 428

12.1.4 Future Therapies for Ovarian Cancer Treatment 428

12.1.5 Future Growth Rate of the Ovarian Cancer Market 428

12.1.6 Current Unmet Needs for Ovarian Cancer Treatment 428

12.1.7 What Ideal Features are Required in a New Drug 428

12.1.8 Past Patient Trends in Ovarian Cancer 428

12.1.9 Referral Pathway 428

13 Ovarian Cancer Therapeutics - Appendix 429

13.1 Definitions 429

13.2 Acronyms 429

13.3 Research Methodology 432

13.3.1 Coverage 433

13.3.2 Secondary Research 433

13.3.3 Forecasting 433

13.3.4 Primary Research 435

13.3.5 Expert Panel Validation 436

13.4 Contact Us 436

13.5 Disclaimer 436

13.6 Sources 436

 

List of Tables

 

Table 1: Ovarian Cancer, AJCC TNM and FIGO Staging System 17

Table 2: Ovarian Cancer, Classification and Treatment Protocol Stages 18

Table 3: Ovarian Cancer Stages I, II & III 20

Table 4: Ovarian Cancer Stage IV 21

Table 5: Ovarian Cancer, Classification of Ovarian Cancer, 2011 27

Table 6: Ovarian Cancer Five-Year Survival Rates 27

Table 7: Ovarian Cancer Chemotherapy Regimens 32

Table 8:Ovarian Cancer Therapeutics Market, Global, Sales Value ($m) by Country, 2002–2011 36

Table 9: Ovarian Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2002–2011 38

Table 10: Ovarian Cancer Therapeutics Market, Global, Patient Volume, 2002–2011 40

Table 11: Ovarian Cancer Therapeutics Market, Global, Treatment Usage Patterns, 2002–2011 41

Table 12: Ovarian Cancer Therapeutics Market, Global, Sales Value ($m), 2011–2020 45

Table 13: Ovarian Cancer Therapeutics Market, Global, Sales Value ($m), 2011–2020 47

Table 14: Ovarian Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2011–2020 48

Table 15: Ovarian Cancer Therapeutics Market, Global, Patient Volume, 2011–2020 50

Table 16: Ovarian Cancer Therapeutics Market, Global, Treatment Usage Patterns, 2011-2020 52

Table 17: Ovarian Cancer Therapeutics Market, Top Seven Countries, Drug Sales ($m), 2002–2011 54

Table 18: Ovarian Cancer Therapeutics Market, Top Seven Countries, Drug Sales ($m), 2011–2020 55

Table 19: Ovarian Cancer Therapeutics Market, The US, Sales Value ($m), 2002–2011 56

Table 20: Ovarian Cancer Therapeutics Market, The US, Annual Cost of Therapy ($), 2002–2011 58

Table 21: Ovarian Cancer Therapeutics Market, The US, Patient Volume, 2002–2011 60

Table 22: Ovarian Cancer Therapeutics Market, The US, Treatment Usage Patterns, 2002–2011 61

Table 23: Ovarian Cancer Therapeutics Market, The US, Sales Value ($m), 2011–2020 66

Table 24: Ovarian Cancer Therapeutics Market, The US, Annual Cost of Therapy ($), 2011–2020 68

Table 25: Ovarian Cancer Therapeutics Market, The US, Patient Volume, 2011–2020 70

Table 26: Ovarian Cancer Therapeutics Market, The US, Treatment Usage Patterns, 2011–2020 71

Table 27: Ovarian Cancer Therapeutics Market, The US, Drug Sales ($m), 2002–2011 73

Table 28: Ovarian Cancer Therapeutics Market, The US, Drug Sales ($m), 2011–2020 74

Table 29: Ovarian Cancer Therapeutics Market, The UK, Sales Value ($m), 2002–2011 76

Table 30: Ovarian Cancer Therapeutics Market, The UK, Annual Cost of Therapy ($), 2002–2011 78

Table 31: Ovarian Cancer Therapeutics Market, The UK, Patient Volume, 2002–2011 80

Table 32: Ovarian Cancer Therapeutics Market, The UK, Treatment Usage Patterns, 2002–2011 82

Table 33: Ovarian Cancer Therapeutics Market, The UK, Sales Value ($m), 2011–2020 87

Table 34: Ovarian Cancer Therapeutics Market, the UK, Annual Cost of Therapy ($), 2011–2020 89

Table 35: Ovarian Cancer Therapeutics Market, The UK, Patient Volume, 2011–2020 91

Table 36: Ovarian Cancer Therapeutics Market, The UK, Treatment Usage Patterns, 2011–2020 93

Table 37: Ovarian Cancer Therapeutics Market, The UK, Drug Sales ($m), 2002–2011 96

Table 38: Ovarian Cancer Therapeutics Market, The UK, Drug Sales ($m), 2011–2020 97

Table 39: Ovarian Cancer Therapeutics Market, Germany, Sales Value ($m), 2002–2011 99

Table 40: Ovarian Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2002–2011 101

Table 41: Ovarian Cancer Therapeutics Market, Germany, Patient Volume, 2002–2011 103

Table 42: Ovarian Cancer Therapeutics Market, Germany, Treatment Usage Patterns, 2002–2011 105

Table 43: Ovarian Cancer Therapeutics Market, Germany, Sales Value ($m), 2011–2020 110

Table 44: Ovarian Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2011–2020 112

Table 45: Ovarian Cancer Therapeutics Market, Germany, Patient Volume, 2011–2020 114

Table 46: Ovarian Cancer Therapeutics Market, Germany, Treatment Usage Patterns, 2011–2020 116

Table 47: Ovarian Cancer Therapeutics Market, Germany, Drug Sales ($m), 2002–2011 119

Table 48: Ovarian Cancer Therapeutics Market, Germany, Drug Sales ($m), 2011–2020 120

Table 49: Ovarian Cancer Therapeutics Market, France, Sales Value ($m), 2002–2011 122

Table 50: Ovarian Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2002–2011 124

Table 51: Ovarian Cancer Therapeutics Market, France, Patient Volume, 2002–2011 126

Table 52: Ovarian Cancer Therapeutics Market, France, Treatment Usage Patterns, 2002–2011 128

Table 53: Ovarian Cancer Therapeutics Market, France, Sales Value ($m), 2011–2020 132

Table 54: Ovarian Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2011–2020 134

Table 55: Ovarian Cancer Therapeutics Market, France, Patient Volume, 2011–2020 136

Table 56: Ovarian Cancer Therapeutics Market, France, Treatment Usage Patterns, 2011–2020 138

Table 57: Ovarian Cancer Therapeutics Market, France, Drug Sales ($m), 2002–2011 141

Table 58: Ovarian Cancer Therapeutics Market, France, Drug Sales ($m), 2011–2020 142

Table 59: Ovarian Cancer Therapeutics Market, Italy, Sales Value ($m), 2002–2011 144

Table 60: Ovarian Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2002–2011 146

Table 61: Ovarian Cancer Therapeutics Market, Italy, Patient Volume, 2002–2011 148

Table 62: Ovarian Cancer Therapeutics Market, Italy, Treatment Usage Patterns, 2002–2011 150

Table 63: Ovarian Cancer Therapeutics Market, Italy, Sales Value ($m), 2011–2020 155

Table 64: Ovarian Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2011–2020 157

Table 65: Ovarian Cancer Therapeutics Market, Italy, Patient Volume, 2011–2020 159

Table 66: Ovarian Cancer Therapeutics Market, Italy, Treatment Usage Patterns, 2011–2020 161

Table 67: Ovarian Cancer Therapeutics Market, Italy, Drug Sales ($m), 2002–2011 164

Table 68: Cancer Therapeutics Market, Italy, Drug Sales ($m), 2011–2020 165

Table 69: Ovarian Cancer Therapeutics Market, Spain, Sales Value ($m), 2002–2011 167

Table 70: Ovarian Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2002–2011 169

Table 71: Ovarian Cancer Therapeutics Market, Spain, Patient Volume, 2002–2011 171

Table 72: Ovarian Cancer Therapeutics Market, Spain, Treatment Usage Patterns, 2002–2011 173

Table 73: Ovarian Cancer Therapeutics Market, Spain, Sales Value ($m), 2011–2020 178

Table 74: Ovarian Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2011–2020 180

Table 75: Ovarian Cancer Therapeutics Market, Spain, Patient Volume, 2011–2020 182

Table 76: Ovarian Cancer Therapeutics Market, Spain, Treatment Usage Patterns, 2011–2020 184

Table 77: Ovarian Cancer Therapeutics Market, Spain, Drug Sales ($m), 2002–2011 187

Table 78: Ovarian Cancer Therapeutics Market, Spain, Drug Sales ($m), 2011–2020 188

Table 79: Ovarian Cancer Therapeutics Market, Japan, Drug Sales ($m), 2002-2011 190

Table 80: Ovarian Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2002–2011 192

Table 81: Ovarian Cancer Therapeutics Market, Japan, Patient Volume, 2002–2011 194

Table 82: Ovarian Cancer Therapeutics Market, Japan, Treatment Usage Patterns, 2002–2011 196

Table 83: Ovarian Cancer Therapeutics Market, Japan, Sales Value ($m), 2011–2020 201

Table 84: Ovarian Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2011–2020 203

Table 85: Ovarian Cancer Therapeutics Market, Japan, Patient Volume, 2011–2020 205

Table 86: Ovarian Cancer Therapeutics Market, Japan, Treatment Usage Patterns, 2011–2020 207

Table 87: Ovarian Cancer Therapeutics Market, Japan, Drug Sales ($m), 2002–2011 210

Table 88: Ovarian Cancer Therapeutics Market, Japan, Drug Sales ($m), 2011–2020 211

Table 89: Ovarian Cancer Therapeutics Market, Brazil, Sales Value ($m), 2002–2011 213

Table 90: Ovarian Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2002–2011 215

Table 91: Ovarian Cancer Therapeutics Market, Brazil, Patient Volume, 2002–2011 216

Table 92: Ovarian Cancer Therapeutics Market, Brazil, Treatment Usage Patterns, 2002–2011 218

Table 93: Ovarian Cancer Therapeutics Market, Brazil, Sales Value ($m), 2011–2020 223

Table 94: Ovarian Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2011–2020 225

Table 95: Ovarian Cancer Therapeutics Market, Brazil, Patient Volume , 2011–2020 226

Table 96: Ovarian Cancer Therapeutics Market, Brazil, Treatment Usage Patterns, 2011–2020 228

Table 97: Ovarian Cancer Therapeutics Market, Russia, Sales Value ($m), 2002–2011 230

Table 98: Ovarian Cancer Therapeutics Market, Russia, Annual Cost of Therapy ($), 2002–2011 231

Table 99: Ovarian Cancer Therapeutics Market, Russia, Patient Volume (Absolute), 2002–2011 232

Table 100: Ovarian Cancer Therapeutics Market, Russia, Treatment Usage Patterns, 2002–2011 234

Table 101: Ovarian Cancer Therapeutics Market, Russia, Sales Value ($m), 2011–2020 239

Table 102: Ovarian Cancer Therapeutics Market, Russia, Annual Cost of Therapy ($), 2011–2020 240

Table 103: Ovarian Cancer Therapeutics Market, Russia, Patient Volume (Absolute), 2011–2020 241

Table 104: Ovarian Cancer Therapeutics Market, Russia, Treatment Usage Patterns, 2011–2020 243

Table 105: Ovarian Cancer Therapeutics Market, India, Sales Value ($m), 2002–2011 246

Table 106: Ovarian Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2002–2011 248

Table 107: Ovarian Cancer Therapeutics Market, India, Patient Volume (Absolute), 2002–2011 249

Table 108: Ovarian Cancer Therapeutics Market, India, Treatment Usage Patterns, 2002–2011 251

Table 109: Ovarian Cancer Therapeutics Market, India, Sales Value ($m), 2011–2020 256

Table 110: Ovarian Cancer Therapeutics Market, India, Annual Cost of Therapy ($), 2011–2020 258

Table 111: Ovarian Cancer Therapeutics Market, India, Patient Volume (Absolute), 2011–2020 259

Table 112: Ovarian Cancer Therapeutics Market, India, Treatment Usage Patterns, 2011–2020 261

Table 113: Ovarian Cancer Therapeutics Market, China, Sales Value ($m), 2002–2011 264

Table 114: Ovarian Cancer Therapeutics Market, China, Annual Cost of Therapy ($), 2002–2011 266

Table 115: Ovarian Cancer Therapeutics Market, China, Patient Volume (Absolute), 2002–2011 267

Table 116: Ovarian Cancer Therapeutics Market, China, Treatment Usage Patterns, 2002–2011 269

Table 117: Ovarian Cancer Therapeutics Market, China, Sales Value ($m), 2011–2020 274

Table 118: Ovarian Cancer Therapeutics Market, China, Annual Cost of Therapy ($), 2011–2020 276

Table 119: Ovarian Cancer Therapeutics Market, China, Patient Volume (Absolute), 2011–2020 277

Table 120: Ovarian Cancer Therapeutics Market, China, Treatment Usage Patterns, 2011–2020 279

Table 121: Ovarian Cancer, Global, Clinical Endpoints – Approved Drugs, 2011 284

Table 122:Ovarian Cancer, Global, Clinical Endpoints for Benchmarking, First-Line Loco-Regional and Advanced/Metastatic Setting, 2011 285

Table 123: Ovarian Cancer, Global, Clinical Endpoints for Benchmarking, Second-Line Loco-Regional and Advanced/Metastatic Setting, 2011 285

Table 124:Ovarian Cancer Therapeutics , Global, Safety Profile of Approved Treatment in Loco-Regional and Advanced/Metastatic Setting, 2011 292

Table 125:Ovarian Cancer Therapeutics Market, Global, Carboplatin, Incidence of Adverse Effects NCIC Study, 2011 298

Table 126:Ovarian Cancer Therapeutics Market, Global, Carboplatin, Incidence of Adverse Effects SWOG Study, 2011 299

Table 127:Ovarian Cancer Therapeutics Market, Global, Carboplatin, Overview of Pivotal Trials, 2011 300

Table 128:Ovarian Cancer Therapeutics Market, Global, Carboplatin, Progression Free Survival, 2011 301

Table 129: Ovarian Cancer Therapeutics Market, Global, Carboplatin, Overall Survival, 2011 301

Table 130:Ovarian Cancer Therapeutics Market, Global, Paclitaxel, Incidence of Adverse Effects in the First-Line Treatment, 2011 309

Table 131:Ovarian Cancer Therapeutics Market, Global, Paclitaxel Incidence of Adverse Effects in the Second-Line Treatment, 2011 310

Table 132:Ovarian Cancer Therapeutics Market, Global, Altretamine, Incidence of Adverse Effects, 2011 315

Table 133:Ovarian Cancer Therapeutics, Hycamtin, Incidence of Adverse Effects, 2011 318

Table 134: Ovarian Cancer Therapeutics , Gemzar, Incidence of Adverse Effects, 2011 323

Table 135:Ovarian Cancer Therapeutics Market, Global, Yondelis, Incidence of Adverse Effects, 2011 327

Table 136: Ovarian Cancer Therapeutics Market, Global, Doxil, Incidence of Adverse Effects, 2011 332

Table 137: Ovarian Cancer, Global, Pipeline by Line of Therapy, 2011 339

Table 138: Ovarian Cancer Pipeline, Pre-Registration, 2011 342

Table 139: Ovarian Cancer Pipeline, Phase III, 2011 343

Table 140: Ovarian Cancer Pipeline, Phase II, 2011 344

Table 141: Ovarian Cancer Pipeline, Phase I, 2011 348

Table 142: Ovarian Cancer Pipeline, Prelinical, 2011 350

Table 143: Ovarian Cancer Pipeline, Discovery, 2011 351

Table 144: Ovarian Cancer, Global, Licensing Agreements, 2009–2011 372

Table 145: Ovarian Cancer, Global, Co-development Agreements, 2009–2011 374

Table 146: Ovarian Cancer Therapeutics Market, Global, Clinical Trials by Status, March 2011 376

Table 147: Ovarian Cancer Therapeutics Market, Global, Clinical Trials by Country, March 2011 377

Table 148: Ovarian Cancer Therapeutics Market, Global, Clinical Trials by Phase, March 2011 378

Table 149:Ovarian Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, March 2011 379

Table 150:Ovarian Cancer Therapeutics Market, Global, Clinical Trials, Leading Sponsors, March 2011 380

Table 151:Ovarian Cancer Therapeutics Market, Global, Clinical Trials, Leading Company Sponsors, March 2011 381

Table 152:Ovarian Cancer Therapeutics Market, Global, Clinical Trials, Average Number of Patients Recruited, March 2011 382

Table 153: Ovarian Cancer, Global, M&A Deals by Geography, 2009–2011 426

Table 154: Ovarian Cancer Therapeutics Market, Global, Treatment Options by Stage, 2011 427

 

List of Figures

 

Figure 1: Ovarian Cancer, Treatment Algorithm, Stage I and II 31

Figure 2: Ovarian Cancer, Treatment Algorithm, Stage III and IV 31

Figure 3: Ovarian Cancer Therapeutics Market, Global, Sales Value ($m), 2002–2011 34

Figure 4: Ovarian Cancer Therapeutics Market, Global, Sales Value ($m) by Country, 2002–2011 36

Figure 5: Ovarian Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2002–2011 38

Figure 6: Ovarian Cancer Therapeutics Market, Global, Patient Volume, 2002–2011 39

Figure 7: Ovarian Cancer Therapeutics Market, Global, Treatment Usage Patterns, 2002–2011 41

Figure 8: Ovarian Cancer Therapeutics Market, Global, Market Drivers and Restraints, 2011 42

Figure 9: Ovarian Cancer Therapeutics Market, Global, the Impact of Historical Events on the Market, 2011 44

Figure 10: Ovarian Cancer Therapeutics Market, Global, Sales Value ($m), 2011–2020 45

Figure 11: Ovarian Cancer Therapeutics Market, Global, Sales Value ($m) by Country, 2011–2020 46

Figure 12: Ovarian Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2011–2020 48

Figure 13: Ovarian Cancer Therapeutics Market, Global, Patient Volume, 2011–2020 50

Figure 14: Ovarian Cancer Therapeutics Market, Global, Treatment Usage Patterns, 2011–2020 52

Figure 15: Ovarian Cancer Therapeutics Market, Global, Future Market Drivers and Restraints, 2011–2020 53

Figure 16: Ovarian Cancer Therapeutics Market, Top Seven Countries, Drug Sales ($m), 2002-2020 54

Figure 17: Ovarian Cancer Therapeutics Market, The US, Sales Value ($m), 2002–2011 56

Figure 18: Ovarian Cancer Therapeutics Market, The US, Annual Cost of Therapy ($), 2002–2011 58

Figure 19: Ovarian Cancer Therapeutics Market, The US, Patient Volume (absolute), 2002–2011 60

Figure 20: Ovarian Cancer Therapeutics Market, The US, Treatment Usage Patterns, 2002–2011 61

Figure 21: Ovarian Cancer Therapeutics Market, The US, Market Drivers and Restraints, 2011 63

Figure 22: Ovarian Cancer Therapeutics Market, The US, The Impact of Historical Events on the Market, 2011 65

Figure 23: Ovarian Cancer Therapeutics Market, The US, Sales Value ($m), 2011–2020 66

Figure 24: Ovarian Cancer Therapeutics Market, The US, Annual Cost of Therapy ($), 2011–2020 68

Figure 25: Ovarian Cancer Therapeutics Market, The US, Patient Volume (Absolute), 2011–2020 70

Figure 26: Ovarian Cancer Therapeutics Market, The US, Treatment Usage Patterns, 2011–2020 71

Figure 27: Ovarian Cancer Therapeutics Market, The US, Future Market Drivers and Restraints, 2011–2020 72

Figure 28: Ovarian Cancer Therapeutics Market, The US, Drug Sales ($m), 2002-2020 73

Figure 29: Ovarian Cancer Therapeutics Market, The UK, Sales Value ($m), 2002–2011 76

Figure 30: Ovarian Cancer Therapeutics Market, The UK, Annual Cost of Therapy ($), 2002–2011 78

Figure 31: Ovarian Cancer Therapeutics Market, The UK, Patient Volume (Absolute), 2002–2011 80

Figure 32: Ovarian Cancer Therapeutics Market, The UK, Treatment Usage Patterns, 2002–2011 82

Figure 33: Ovarian Cancer Therapeutics Market, The UK, Market Drivers and Restraints, 2011 84

Figure 34: Ovarian Cancer Therapeutics Market, The UK, The Impact of Historical Events on the Market, 2011 86

Figure 35: Ovarian Cancer Therapeutics Market, The UK, Sales Value ($m), 2011–2020 87

Figure 36: Ovarian Cancer Therapeutics Market, The UK, Annual Cost of Therapy ($), 2011–2020 89

Figure 37: Ovarian Cancer Therapeutics Market, The UK, Patient Volume (Absolute), 2011–2020 91

Figure 38: Ovarian Cancer Therapeutics Market, The UK, Treatment Usage Patterns, 2011–2020 93

Figure 39: Ovarian Cancer Therapeutics Market, The UK, Future Market Drivers and Restraints, 2011–2020 95

Figure 40: Ovarian Cancer Therapeutics Market, The UK, Drug Sales ($m), 2002-2020 96

Figure 41: Ovarian Cancer Therapeutics Market, Germany, Sales Value ($m), 2002–2011 99

Figure 42: Ovarian Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2002–2011 101

Figure 43: Ovarian Cancer Therapeutics Market, Germany, Patient Volume (Absolute), 2002–2011 103

Figure 44: Ovarian Cancer Therapeutics Market, Germany, Treatment Usage Patterns, 2002–2011 105

Figure 45: Ovarian Cancer Therapeutics Market, Germany, Market Drivers and Restraints, 2011 107

Figure 46: Ovarian Cancer Therapeutics Market, Germany, The Impact of Historical Events on the Market, 2011 109

Figure 47: Ovarian Cancer Therapeutics Market, Germany, Sales Value ($m), 2011–2020 110

Figure 48: Ovarian Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2011–2020 112

Figure 49: Ovarian Cancer Therapeutics Market, Germany, Patient Volume (Absolute), 2011–2020 114

Figure 50: Ovarian Cancer Therapeutics Market, Germany, Treatment Usage Patterns, 2011–2020 116

Figure 51: Ovarian Cancer Therapeutics Market, Germany, Future Market Drivers and Restraints, 2011–2020 118

Figure 52: Ovarian Cancer Therapeutics Market, Germany, Drug Sales ($m), 2002-2020 119

Figure 53: Ovarian Cancer Therapeutics Market, France, Sales Value ($m), 2002–2011 122

Figure 54: Ovarian Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2002–2011 124

Figure 55: Ovarian Cancer Therapeutics Market, France, Patient Volume (Absolute), 2002–2011 126

Figure 56: Ovarian Cancer Therapeutics Market, France, Treatment Usage Patterns, 2002–2011 128

Figure 57: Ovarian Cancer Therapeutics Market, France, Market Drivers and Restraints, 2011 130

Figure 58: Ovarian Cancer Therapeutics Market, France, The Impact of Historical Events on the Market, 2011 131

Figure 59: Ovarian Cancer Therapeutics Market, France, Sales Value ($m), 2011–2020 132

Figure 60: Ovarian Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2011–2020 134

Figure 61: Ovarian Cancer Therapeutics Market, France, Patient Volume (Absolute), 2011–2020 136

Figure 62: Ovarian Cancer Therapeutics Market, France, Treatment Usage Patterns, 2011–2020 138

Figure 63: Ovarian Cancer Therapeutics Market, France, Future Market Drivers and Restraints, 2011–2020 140

Figure 64: Ovarian Cancer Therapeutics Market, France, Drug Sales ($m), 2002–2020 141

Figure 65: Ovarian Cancer Therapeutics Market, Italy, Sales Value ($m), 2002–2011 144

Figure 66: Ovarian Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2002–2011 146

Figure 67: Ovarian Cancer Therapeutics Market, Italy, Patient Volume (Absolute), 2002–2011 148

Figure 68: Ovarian Cancer Therapeutics Market, Italy, Treatment Usage Patterns, 2002–2011 150

Figure 69: Ovarian Cancer Therapeutics Market, Italy, Market Drivers and Restraints, 2011 152

Figure 70: Ovarian Cancer Therapeutics Market, Italy, The Impact of Historical Events on the Market, 2011 154

Figure 71: Ovarian Cancer Therapeutics Market, Italy, Sales Value ($m), 2011–2020 155

Figure 72: Ovarian Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2011–2020 157

Figure 73: Ovarian Cancer Therapeutics Market, Italy, Patient Volume (Absolute), 2011–2020 159

Figure 74: Ovarian Cancer Therapeutics Market, Italy, Treatment Usage Patterns, 2011–2020 161

Figure 75: Ovarian Cancer Therapeutics Market, Italy, Future Market Drivers and Restraints, 2011–2020 163

Figure 76: Ovarian Cancer Therapeutics Market, Italy, Drug Sales ($m), 2002-2020 164

Figure 77: Ovarian Cancer Therapeutics Market, Spain, Sales Value ($m), 2002–2011 167

Figure 78: Ovarian Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2002–2011 169

Figure 79: Ovarian Cancer Therapeutics Market, Spain, Patient Volume (Absolute), 2002–2011 171

Figure 80: Ovarian Cancer Therapeutics Market, Spain, Treatment Usage Patterns, 2002–2011 173

Figure 81: Ovarian Cancer Therapeutics Market, Spain, Market Drivers and Restraints, 2011 175

Figure 82: Ovarian Cancer Therapeutics Market, Spain, The Impact of Historical Events on the Market, 2011 177

Figure 83: Ovarian Cancer Therapeutics Market, Spain, Sales Value ($m), 2011–2020 178

Figure 84: Ovarian Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2011–2020 180

Figure 85: Ovarian Cancer Therapeutics Market, Spain, Patient Volume (Absolute), 2011–2020 182

Figure 86: Ovarian Cancer Therapeutics Market, Spain, Treatment Usage Patterns, 2011–2020 184

Figure 87: Ovarian Cancer Therapeutics Market, Spain, Future Market Drivers and Restraints, 2011–2020 186

Figure 88: Ovarian Cancer Therapeutics Market, Spain, Drug Sales ($m), 2002-2020 187

Figure 89: Ovarian Cancer Therapeutics Market, Japan, Drug Sales ($m), 2002-2011 190

Figure 90: Ovarian Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2002–2011 192

Figure 91: Ovarian Cancer Therapeutics Market, Japan, Patient Volume (Absolute), 2002–2011 194

Figure 92: Ovarian Cancer Therapeutics Market, Japan, Treatment Usage Patterns, 2002–2011 196

Figure 93: Ovarian Cancer Therapeutics Market, Japan, Market Drivers and Restraints, 2011 198

Figure 94: Ovarian Cancer Therapeutics Market, Japan, Impact of Historical Events on the Market, 2011 200

Figure 95: Ovarian Cancer Therapeutics Market, Japan, Sales Value ($m), 2011–2020 201

Figure 96: Ovarian Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2011–2020 203

Figure 97: Ovarian Cancer Therapeutics Market, Japan, Patient Volume (Absolute), 2011–2020 205

Figure 98: Ovarian Cancer Therapeutics Market, Japan, Treatment Usage Patterns, 2011–2020 207

Figure 99: Ovarian Cancer Therapeutics Market, Japan, Future Market Drivers and Restraints, 2011–2020 209

Figure 100: Ovarian Cancer Therapeutics Market, Japan, Drug Sales ($m), 2002-2020 210

Figure 101: Ovarian Cancer Therapeutics Market, Brazil, Sales Value ($m), 2002–2011 213

Figure 102: Ovarian Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2002–2011 215

Figure 103: Ovarian Cancer Therapeutics Market, Brazil, Patient Volume (Absolute), 2002–2011 216

Figure 104: Ovarian Cancer Therapeutics Market, Brazil, Treatment Usage Patterns, 2002–2011 218

Figure 105: Ovarian Cancer Therapeutics Market, Brazil, Market Drivers and Restraints, 2011 220

Figure 106: Ovarian Cancer Therapeutics Market, Brazil, The Impact of Historical Events on the Market, 2011 222

Figure 107: Ovarian Cancer Therapeutics Market, Brazil, Sales Value ($m), 2011–2020 223

Figure 108: Ovarian Cancer Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2011–2020 225

Figure 109: Ovarian Cancer Therapeutics Market, Brazil, Patient Volume (Absolute), 2011–2020 226

Figure 110: Ovarian Cancer Therapeutics Market, Brazil, Treatment Usage Patterns, 2011–2020 228

Figure 111: Ovarian Cancer Therapeutics Market, Brazil, Future Market Drivers and Restraints, 2011–2020 229

Figure 112: Ovarian Cancer Therapeutics Market, Russia, Sales Value ($m), 2002–2011 230

Figure 113: Ovarian Cancer Therapeutics Market, Russia, Annual Cost of Therapy ($), 2002–2011 231

Figure 114: Ovarian Cancer Therapeutics Market, Russia, Patient Volume (Absolute), 2002–2011 232

Figure 115: Ovarian Cancer Therapeutics Market, Russia, Treatment Usage Patterns, 2002–2011 234

Figure 116: Ovarian Cancer Therapeutics Market, Russia, Market Drivers and Restraints, 2011 236

Figure 117: Ovarian Cance

To order this report:

Therapy Industry: Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020

More Market Research Report

Check our Industry Analysis and Insights

Nicolas Bombourg Reportlinker Email: nicolasbombourg@reportlinker.com US: (805)652-2626 Intl: +1 805-652-2626

 


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved


Related medicine technology :

1. Global Kidney Cancer Drugs Industry
2. Trovagene to Study Trans-Renal KRAS Mutation Detection in Pancreatic Cancer
3. Prostate Cancer Center of New Jersey the Latest Center to Achieve High Honor of ACR-ASTRO Accreditation
4. Lifeline Biotechnologies, Inc. Receives Patent Award, a Device for Breast Tissue Temperature Analysis for Determining Cancer Conditions
5. U.S. FDA Grants Priority Review to the New Drug Application for Bayers Regorafenib to Treat Patients with Metastatic Colorectal Cancer
6. Aethlon Medical (AEMD) Note: Cancer Treatment Publication Authored by Aethlon Medical Researchers Now Available
7. Elektas Gamma Knife and Radiation Therapy Systems for Cancer Treatment Take Top Three Places in 2012s Best in KLAS for Radiation Therapy
8. Healthscope to commercially launch Circadians Cancers of Unknown Primary Diagnostic Test
9. Pinnacle Biologics and INTERmedic Medical Devices announce strategic manufacturing and distribution agreement for cancer laser technology
10. Breast Cancer Detection and Treatment Recovers Slowly from Big Losses During Recession
11. U.K. Cancer Patient is Worlds First to Benefit from Treatment Combining Elektas New Beam-shaping Innovation and High-speed Arc Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... environments  Oticon , industry leaders in ... the launch of Oticon Opn ™, the world,s ... world of possibilities for IoT devices.      ... Opn, Oticon introduces a number of ,world firsts,: ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... ... TherapySites, the leading website and online marketing ... Association. This new relationship allows TherapySites to continue to extend their online ... and promotional offers. , "TCA is extremely excited about this new partnership, as ...
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to ... of individuals in the United States and Canada wear eyeglasses. Once considered to be ... vision and make a fashion statement. Even celebrities use glasses as a way of ...
(Date:6/26/2016)... ... ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect Plugin ... whole new perspective by using the title layers in ProSlice Levels to split-up ... Levels contains over 30 Different presets to choose from. FCPX users can ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
Breaking Medicine News(10 mins):